7-tert.butoxyformamido-6,7,8,9-tetrahydropyrido<1,2-a>indole | 131849-33-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-tert.butoxyformamido-6,7,8,9-tetrahydropyrido<1,2-a>indole
• 英文别名: tert-butyl (6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl)carbamate；7-tert.butoxyformamido-6,7,8,9-tetrahydropyrido[1,2-a]indole；tert-butyl N-(6,7,8,9-tetrahydropyrido[1,2-a]indol-7-yl)carbamate
• CAS: 131849-33-7
• 化学式: C₁₇H₂₂N₂O₂
• 分子量: 286.374
• InChiKey: MVPYWSIRWLDPKF-UHFFFAOYSA-N

物化性质

• 沸点：
  469.3±34.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  43.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-tert.butoxyformamido-6,7,8,9-tetrahydropyrido<1,2-a>indole 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 70.08h， 生成 {10-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-furan-3-yl]-6,7,8,9-tetrahydro-pyrido[1,2-a]indol-7-yl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction

  摘要：

  The protein kinase inhibitor staurosporine has been used to design a series of selective bisindolylmaleimide inhibitors of protein kinase C (PKC). Guided by molecular graphics, conformational restriction of the cationic side chain has led to ATP competitive inhibitors of improved potency and selectivity. Two compounds have been further evaluated and were shown to inhibit PKC of human origin and prevent T-cell activation in a human allogeneic mixed lymphocyte reaction. One of these compounds was orally absorbed in mice and antagonized a phorbol ester induced paw edema in a dose-dependent manner. This compound also selectively inhibited the secondary T-cell mediated response in a developing adjuvant arthritis model in rats and provides evidence for the potential use of PKC inhibitors as therapeutic immunomodulators.

  DOI：

  10.1021/jm00053a003
• 作为产物：
  描述：

  (E)-ethyl 3-(1H-indol-2-yl)acrylate 在 palladium on activated charcoal 乙酸铵 、 palladium on activated charcoal 、 potassium tert-butylate 、 氢气 、 silica gel 、 sodium hydride 、 sodium cyanoborohydride 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 35.0h， 生成 7-tert.butoxyformamido-6,7,8,9-tetrahydropyrido<1,2-a>indole
  参考文献：
  名称：

  Dieckmann / ring扩容方法制备四氢吡啶并和四氢氮杂环庚烷-[1,2-a]吲哚

  摘要：

  据报道，一般的Dieckmann /环膨胀方法用于稠合的[1,2-a]吲哚体系。这种方法已允许合成制备一系列有效和选择性的蛋白激酶C抑制剂所需的多种取代系统。

  DOI：

  10.1016/s0040-4020(01)86471-1

文献信息

• [EN] 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-A]INDOL ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS D'ACIDE 7-(HÉTÉROARYL-AMINO)-6,7,8,9-TÉTRAHYDROPYRIDO[1,2-A]INDOLACÉTIQUE ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR AUX PROSTAGLANDINES D2
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2012140612A1

  公开（公告）日：2012-10-18

  The present invention relates to 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives of the formula (I), wherein R1, R2, R3 and R4 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.

  本发明涉及公式（I）中的7-(杂环芳基氨基)-6,7,8,9-四氢吡啶并[1,2-a]吲哚乙酸衍生物，其中R1、R2、R3和R4如描述中所述，并且它们作为前列腺素受体调节剂，尤其作为前列腺素D2受体调节剂，在治疗各种前列腺素介导的疾病和紊乱中的用途，以及包含这些化合物的药物组合物和其制备方法。
• Substituierte Pyrrole
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0384349A1

  公开（公告）日：1990-08-29

  Die Pyrrolderivate der Formel worin R¹ bis R⁸, R, X, Y und m die in der Beschreibung angegebene Bedeutung haben, sind therapeutisch aktive Sub­stanzen, insbesondere zur Verwendung als antiinflamma­torisch, immunologisch, onkologisch, bronchopulmonär und kardiovaskulär aktive Substanzen oder als Wirkstoffe in der Behandlung von Asthma oder AIDS. Sie werden hergestellt aus entsprechenden Furandion­derivaten, worin O für =N-R, X und Y steht.

  式中的吡咯衍生物 其中 R¹ 至 R⁸、R、X、Y 和 m 具有说明中给出的含义，是具有治疗活性的物质，特别是可用作抗炎、免疫、肿瘤、支气管和心血管活性物质或治疗哮喘或艾滋病的活性物质。 它们由相应的呋喃二酮衍生物制得，其中 O 代表 =N-R、X 和 Y。
• US5721245A
  申请人：——

  公开号：US5721245A

  公开（公告）日：1998-02-24
• A Dieckmann/ring expansion approach to tetrahydropyrido- and tetrahydroazepino-[1,2-a]indoles
  作者：Rino A. Bit、Peter D. Davis、Christopher H. Hill、Elizabeth Keech、David R. Vesey

  DOI：10.1016/s0040-4020(01)86471-1

  日期：1991.1

  A general Dieckmann/ring expansion approach to fused [1,2-a]indole systems is reported. This approach has allowed the synthesis of a large variety of substituted systems required for the preparation of a series of potent and selective inhibitors of Protein Kinase C.

  据报道，一般的Dieckmann /环膨胀方法用于稠合的[1,2-a]吲哚体系。这种方法已允许合成制备一系列有效和选择性的蛋白激酶C抑制剂所需的多种取代系统。
• Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction
  作者：Rino A. Bit、Peter D. Davis、Lucy H. Elliott、William Harris、Christopher H. Hill、Elizabeth Keech、Hari Kumar、Geoffrey Lawton、Anna Maw、John S. Nixon、David R. Vesey、Julie Wadsworth、Sandra E. Wilkinson

  DOI：10.1021/jm00053a003

  日期：1993.1

  The protein kinase inhibitor staurosporine has been used to design a series of selective bisindolylmaleimide inhibitors of protein kinase C (PKC). Guided by molecular graphics, conformational restriction of the cationic side chain has led to ATP competitive inhibitors of improved potency and selectivity. Two compounds have been further evaluated and were shown to inhibit PKC of human origin and prevent T-cell activation in a human allogeneic mixed lymphocyte reaction. One of these compounds was orally absorbed in mice and antagonized a phorbol ester induced paw edema in a dose-dependent manner. This compound also selectively inhibited the secondary T-cell mediated response in a developing adjuvant arthritis model in rats and provides evidence for the potential use of PKC inhibitors as therapeutic immunomodulators.